Brief: TC Biopharm Receives MHRA And Research Ethics Committee Approvals To Initiate Phase 2B/3 Clinical Trials For Treatment Of Acute Myeloid Leukemia

TC Biopharm (Holdings)

23/03/2022 13:23

March 23 (Reuters) - TC BioPharm Ltd  T0Uy.F :
    * TC BIOPHARM RECEIVES MHRA AND RESEARCH ETHICS COMMITTEE
APPROVALS TO INITIATE PHASE 2B/3 CLINICAL TRIALS FOR TREATMENT
OF ACUTE MYELOID LEUKEMIA
    * TC BIOPHARM  - TRIAL ENROLLMENT EXPECTED TO BEGIN DURING
FIRST
HALF OF 2022
    * TC BIOPHARM - PHASE 2/3 TRIALS WILL BEGIN ENROLLMENT IN
FIRST
HALF OF 2022 IN UK WITH EXPANSION INTO US FOLLOWING SHORTLY
THEREAFTER

Source text for Eikon:  ID:nPnb3gYHSa 
Further company coverage:  T0Uy.F 

 ((Reuters.Briefs@thomsonreuters.com;))